Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone

Cancer Letters

Volumn 206, Issue 2, 2004, Pages 149-157

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer treatment; Geldanamycin; Heat shock; Herbimycin; Hsp90 chaperone; Hsp90 inhibitor 17AAG; Novabiocin; Oncogenes; Protein folding; Radicicol

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; RADICICOL; UNCLASSIFIED DRUG;

BREAST CARCINOMA; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DRUG POTENCY; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; KIDNEY CARCINOMA; LIVER TOXICITY; MELANOMA; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT;

EID: 1542298267     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.08.032     Document Type: Article

References (51)

1. Lund D.P. Molecular Chaperones in the Cell. 2001;Oxford University Press, Oxford.
2. Sangster T.A., Queitsch C., Lindquist S. Hsp90 and chromatin. Where is the link? Cell Cycle. 23:2003;166-168.
3. Rutherford S.L., Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature. 396:1998;336-342.
4. Jolly C., Morimoto R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst. 92:2000;1564-1572.
5. Scheibel T., Buchner J. The Hsp90 complex-A super-chaperone machine as a novel drug target. Biochem. Pharmacol. 56:1998;675-682.
6. Smith D.F., Whitesell L., Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol. Rev. 50:1998;493-513.
7. Neckers L., Schulte T.W., Mimnaugh E. Geldanmycin as a potential anticancer agent: its molecular target and biochemical activity. Invest. New Drugs. 17:1999;361-373.
8. Maloney A., Workman P. Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Exp. Opin. Biol. Ther. 2:2002;3-24.
9. Workman P. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. Cancer Detect. Prevent. 26:2002;405-410.
10. Isaacs J.S., Xu W., Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 3:2003;213-217.
11. Banerji U., Clarke P., Walton M., O'Donnell A., Raynaud F., Turner A., et al. Preclinical and clinical activity of the molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in malignant melanoma. Proc. Am. Assoc. Cancer Res. 2003;677-678.
12. Buchner J. Hsp90 and Co. - a holding for folding. Trends Biochem. Sci. 24:1999;136-141.
13. De Carcer G., Avides M.C., Lallena M.J., Glover D.M., Gonzalez C. Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability. Eur. Mol. Biol. Org. J. 20:2001;2878-2884.
14. Goes F.S., Martin J. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1amd Swe1. Eur. J. Biochem. 268:2001;2281-2289.
15. Queitsch C., Sangster T.A., Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature. 417:2002;618-624.
16. Lindquist S.L., Henikoff S. Self-perpetuating structural states in biology, disease and genetics. Proc. Natl. Acad. Sci. USA. 99:(Suppl. 4):2002;16377.
17. Sollars V., Lu X., Xiao L., Wang X., Garfinkel M.D., Ruden D.M. Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nat. Genet. 33:2003;70-74.
18. Prodromou C., Pearl L.H. Structure and in vivo function of Hsp90. Curr. Opin. Struct. Biol. 10:2000;46-51.
19. Meyer P., Prodromou C., Hu B., Vaughan C., Panaretou B., Piper W.P., Pearl L.H. Structural and functional analysis of the middle segment of Hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol. Cell. 11:2003;647-658.
20. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Pier P.W., Pearl L.H. Identification and structural characterisation of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 90:1997;65-70.
21. Stebbings C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumour agent. Cell. 89:1997;239-250.
22. Dutta R., Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 25:2000;24-28.
23. Panaretou B., Siligardi G., Meyer P., Maloney A., Sullivan J.K., Singh S., et al. Activation of the ATPase activity of Hsp90 by the stress-regulated co-chaperone Aha1. Mol. Cell. 10:2002;1307-1318.
24. Ferrarini M., Helta S., Zocchi M.R., Rugarli C. Unusual expression and localisation of heat shock proteins in human tumour cells. Int. J. Cancer. 16:1992;613-619.
25. Weinstein I.B. Addiction to oncogenes. Science. 297:2002;63-64.
26. Workman P. Cancer genome targets - RAF-ing up tumour cells to overcome oncogene addiction. Exp. Rev. Anticancer Ther. 2:2002;611-614.
27. Evan G., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer research. Nature. 411:2001;342-348.
28. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
29. Prodromou C., Roe S.M., Piper P.W., Pearl L.H. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone. Nat. Struct. Biol. 4:1997;477-482.
30. Panaretou B., Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. Eur. Mol. Biol. Org. J. 17:1998;4829-4836.
31. Roe S.M., Prodromou C., Brien R.O., Ladbury J.E., Piper P.W., Pearl L.H. The structural basis for inhibition of the Hsp90 molecular chaperone, by the anti-tumour antibiotics radicicol and geldanamycin. J. Med. Chem. 42:1999;260-266.
32. Connell P., Ballinger C.A., Jiang J.H., Wu Y.X., Thompson L.J., Hohfeld J., Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3:2001;93-96.
33. Ballinger C.A., Connell P., Wu Y., Hu Z., Thompson L.J., Yin L.Y., Patterson C. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19:1999;4535-4545.
34. Soga S., Neckers L.M., Schulte T.W., Shiotsu Y., Akasaka K., Narumi H., et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 59:1999;2931-2938.
35. Supko J.G., Hickman R.L., Greever M.R. L. Malspies, Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent. Cancer Chemother. Pharmacol. 36:1995;305-310.
36. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT-diaphorase expression and tumour cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91:1999;1940-1949.
37. Sausville E.A., Tomaszewski J.E., Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets. 3:2003;377-383.
38. Banerji U., O'Donnell A., Scurr M., Benson C., Brock C., Hanwell J., et al. A pharmacokinetically (Pk)-pharmcodynamically (Pd) driven phase 1 trial of the Hsp90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG). Proc. Am. Assoc. Cancer Res. 43:2002;272. [Abstract 1352].
39. Chiosis G., Huezo H., Rosen N., Mimnaugh E., Whitesell L., Neckers L. 17AAG: low target binding affinity and potent cell activity - finding an explanation. Mol. Cancer Ther. 2:2003;123-129.
40. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther. 2:2003;131-138.
41. Smith V., Sausville E., Camalier R., Fiebig H.H., Burger A.M. 17-DMAG (NSC 70745), a water soluble geldanamycin analog, has superior in vitro and in vivo antitumour activity compared to the hsp90 inhibitor 17AAG. Eur. J. Cancer. 38:2002;S60.
42. Soga S., Sharma S.V., Shiotsu Y. Stereospecific antitumour activity of radicicol oxime derivatives. Cancer Chemother. Pharmacol. 48:2001;435-445.
43. Marcu M.G., Schulte T.W., Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signalling proteins. J. Natl. Cancer Inst. 92:2000;242-248.
44. Marcu M.G., Chadli A., Bouhouche I., Catelli M., Neckers L. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275:2000;37181-37186.
45. Itoh H., Ogura M., Komatsuda A., Wakui H., Miura A.B., Tashima Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem. J. 343:1999;697-703.
46. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8:2001;289-299.
47. Chiosis G., Lucas B., Shtil A., Huezo H., Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10:2002;3555-3564.
48. Aherne W., Maloney A., Sharp S., Clarke P., Walton M., Hardcastle A., et al. Discovery of a novel synthetic inhibitor of the Hsp90 molecular chaperone. Proc. Am. Assoc. Cancer Res. 44:2003;799.
49. Workman P. Scoring a bull's-eye against cancer genome targets. Curr. Opin. Pharmacol. 1:2001;342-352.
50. Kamal A., Thao L., Sensitaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425:2003;407-410.
51. Clarke P.A., Hostein I., Banerji U., Di Stefano F., Maloney A., Walton M., et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of thee hsp90 molecular chaperone. Oncogene. 19:2000;4125-4133.